Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer

Rongbin Zhou,Dingjin Lu,Junhao Mi,Chengbang Wang,Wenhao Lu,Zuheng Wang,Xiao Li,Chunmeng Wei,Huiyong Zhang,Jin Ji,Yifeng Zhang,Duobing Zhang,Fubo Wang
DOI: https://doi.org/10.1038/s41598-024-61679-y
IF: 4.6
2024-06-21
Scientific Reports
Abstract:Disulfidptosis, a newly identified programmed cell death pathway in prostate cancer (PCa), is closely associated with intracellular disulfide stress and glycolysis. This study aims to elucidate the roles of disulfidptosis-related genes (DRGs) in the pathogenesis and progression of PCa, with the goal of improving diagnostic and therapeutic approaches. We analyzed PCa datasets and normal tissue transcriptome data from TCGA, GEO, and MSKCC. Using consensus clustering analysis and LASSO regression, we developed a risk scoring model, which was validated in an independent cohort. The model's predictive accuracy was confirmed through Kaplan–Meier curves, receiver operating characteristic (ROC) curves, and nomograms. Additionally, we explored the relationship between the risk score and immune cell infiltration, and examined the tumor microenvironment and somatic mutations across different risk groups. We also investigated responses to immunotherapy and drug sensitivity. Our analysis identified two disulfidosis subtypes with significant differences in survival, immune environments, and treatment responses. According to our risk score, the high-risk group exhibited poorer progression-free survival (PFS) and higher tumor mutational burden (TMB), associated with increased immune suppression. Functional enrichment analysis linked high-risk features to key cancer pathways, including the IL-17 signaling pathway. Moreover, drug sensitivity analysis revealed varied responses to chemotherapy, suggesting the potential for disulfidosis-based personalized treatment strategies. Notably, we identified PROK1 as a crucial prognostic marker in PCa, with its reduced expression correlating with disease progression. In summary, our study comprehensively assessed the clinical implications of DRGs in PCa progression and prognosis, offering vital insights for tailored precision medicine approaches.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to address the role of disulfide stress-related genes (DRGs) in the occurrence and development of prostate cancer (PCa) and explore their potential as prognostic biomarkers. Specifically, the study objectives include: 1. **Elucidating the role of DRGs**: By analyzing the expression of DRGs in prostate cancer and their association with patient prognosis, the study investigates the role of these genes in the pathogenesis of prostate cancer. 2. **Developing a risk scoring model**: Using methods such as consensus clustering analysis and LASSO regression, the study constructs a risk scoring model to predict the prognosis of prostate cancer patients and validates the model's effectiveness in an independent cohort. 3. **Evaluating immune infiltration and tumor microenvironment**: The study examines the relationship between risk scores and immune cell infiltration, tumor microenvironment characteristics, and immune therapy response to understand the differences between different risk groups. 4. **Personalized treatment strategies**: Based on the biological characteristics related to disulfide stress, the study proposes potential personalized treatment strategies, particularly in terms of chemotherapy sensitivity and immune checkpoint inhibitor response. 5. **Identifying key prognostic markers**: The study identifies key genes, such as PROK1, as important prognostic markers for prostate cancer, with low expression associated with disease progression. In summary, this research comprehensively evaluates the clinical significance of DRGs in the progression and prognosis of prostate cancer, providing important insights and new strategies for precision medicine.